BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

...in a series E round to start midyear a pair of Phase I/II trials of EO2401...
...did existing investors Seventure, Health for Life Capital, Principia, Omnes Capital and Nestlé Health Science. EO2401...
BioCentury | Mar 20, 2019
Company News

Enterome, Dana-Farber partner on microbiome-derived mimics of tumor antigens

...involve EO2401, the first compound from Enterome’s onco-mimic discovery platform, or the company’s preclinical candidates. EO2401...
...trials this year to treat recurrent glioblastoma multiforme. Mary Romeo, Staff Writer Dana-Farber Cancer Institute Enterome Bioscience S.A. Institut Gustave-Roussy EO2401 microbiome...
Items per page:
1 - 2 of 2